Evidence map›Paper›PMID 30701027›Full record

ArticleOncotarget2018

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma.

Roberto Carmagnani Pestana, Manal M Hassan, Reham Abdel-Wahab, Yehia I Abugabal, Lauren M Girard, Donghui Li, Ping Chang, Kanwal Raghav, Jeff Morris, Robert A Wolff and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. ElevatedFrontiers in immunology · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Roberto Carmagnani PestanaDepartment of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manal M HassanDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reham Abdel-WahabDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yehia I AbugabalDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren M GirardDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Donghui LiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ping ChangDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kanwal RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeff MorrisDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert A WolffDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Asif RashidDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hesham M AminDepartment of Hemopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USAssiut University Hospitals · EG

Funding

Molecular Epidemiology of Chronic Liver DiseasesK07CA106458 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HASSAN, MANAL METWALLY · 2005 to 2009
$681k
Novel Point-of-Care Tool to Predict Response to Sorafenib in Hepatocellular CarcinomaR21CA190945 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KASEB, AHMED · 2016 to 2017
$383k
Integrating plasma IGF-1 into novel classification of hepatocellular carcinomaR21CA170035 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KASEB, AHMED · 2012 to 2013
$366k
Hepatitis Virus, Alcohol Exposure and Oxidative StressR03ES011481 · NIEHS · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI HASSAN, MANAL M · 2001 to 2002
$150k
NCI NIH HHS K07 CA106458NCI NIH HHS R21 CA170035NCI NIH HHS R21 CA190945NIEHS NIH HHS R03 ES011481
6 · The paper itself

Abstract

Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) play critical roles in angiogenesis in hepatocellular carcinoma (HCC). In addition, recent data suggest that Ang-1/Ang-2 are involved in regulating the immune response. The aim of our study was to explore the clinical prognostic significance of plasma Ang-1 and Ang-2 in HCC. We prospectively enrolled and collected data and blood samples from 767 HCC patients treated at MD Anderson Cancer Center between 2001 and 2014. Controls consisted of cirrhotic patients (

Indexed as

angiogenesisangiopoietin-1angiopoietin-2cirrhosishepatocellular carcinoma

Identifiers

PMID30701027
PMCPMC6340869
OpenAlexW2908430335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.